![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-new20logo-01-3.png\")
<\/p>\n<\/p>\n
DelveInsight’s <\/span>Graft Versus Host Disease (GvHD)<\/strong><\/a> report provides an overview of the disease and market size of GvHD for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, the UK) and Japan.<\/span><\/p>\n Some Key highlights from the <\/strong>Graft Versus Host Disease Market Report<\/strong><\/a><\/p>\n For more information, request sample page @ <\/span>Graft Versus Host Disease Market Insights<\/strong><\/a><\/p>\n The <\/span>Graft Versus Host Disease market report<\/strong><\/a> provides current treatment practices, emerging drugs Graft Versus Host Disease market share of the individual therapies, current and forecasted Graft Versus<\/span><\/p>\n Host Disease market size during the study period of 2017-30 in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France), and Japan).<\/span><\/p>\n Graft Versus Host Disease: Overview<\/strong><\/a><\/p>\n Graft Versus Host Disease (GvHD) is a condition marked by inflammation in various organs. GvHD is typically associated with stem cell and bone marrow transplants. The donor’s immune system’s white blood cells, which reside inside the donated tissue (the graft), identify the recipient (the host) as a foreign body (non-self). The white blood cells in the transplanted tissue then invade the cells in the recipient’s body, resulting in GvHD.<\/span><\/p>\n Read more about <\/span>GvHD Treatment Options and Trends<\/strong><\/a><\/p>\n There are two forms of GvHD:<\/span><\/p>\n Graft Versus Host Disease Epidemiology Segmentation<\/strong><\/p>\n Get more details about epidemiology @ <\/span>Graft Versus Host Disease Epidemiology<\/strong><\/a><\/p>\n Graft Versus Host Disease Treatment Landscape<\/strong><\/p>\n The major therapies used in treatment and prevention of GvHD are classified into:<\/span><\/p>\n Graft Versus Host Disease Market<\/strong><\/a><\/p>\n Key companies including Incyte Corporation, Novartis, Methoxsalen, Elsalys Biotech, Kadmon Corporation, Kamada, Cellect Biotechnology, Syndax Pharmaceuticals, among others are expected to enter the GvHD market with new therapies.<\/span><\/p>\n The introduction of Ruxolitinib (Incyte Corporation\/Novartis), Itacitinib (Incyte Corporation), Uvadex (Methoxsalen), Leukotac (Elsalys Biotech), KD025 (Kadmon Corporation), Glassia (Kamada), ApoGraft (Cellect Biotechnology) and SNDX-6352 (Syndax Pharmaceuticals) are expected to give the GvHD market a significant boost in the forecast period 2017-30 in the 7MM.<\/span><\/p>\n Furthermore, extensive R&D in the domain, as well as increasing GvHD prevalence, are driving the GvHD market forward.<\/span><\/p>\n Graft Versus Host Disease Pipeline Therapies and Key Companies<\/strong><\/p>\n![\"Graft](\"http:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Graft%20Versus%20Host%20Disease%20Market%20Insights-01.jpg?1621574713041\")
<\/span><\/p>\n\n
\n
\n
\n
\n